Join WHO for a webinar to launch the guideline on the use of HPV genotyping within cervical cancer screening and treatment. The recommendations provide countries with evidence-based screening and treatment options using HPV limited and extended genotyping, to support implementation in line with national health system and service delivery capacity.
Why this matters
The WHO Global Strategy for the elimination of cervical cancer calls for 70% of women to be screened using a high-performance test by ages 35 and 45. Quality assured high-performance HPV testing is recommended as the preferred approach.
High-performance limited and extended HPV DNA genotyping allow programmes to better identify women at highest risk and prioritise follow-up and treatment. However, many screening programmes face a persistent challenge: women who test positive do not complete the pathway to treatment.
These updated recommendations respond directly to this gap. They emphasize the importance of choosing screening approaches that are feasible for health systems and ensure continuity of care from testing to treatment.
About the launch
The webinar introduced the updated WHO recommendations and their implications for national programmes. It presented screening algorithms that include the role of HPV DNA genotyping followed by different management strategies in line with programme capacity, and shared implementation experience from countries advancing HPV-based screening.
View the webinar recordings here:
Session 1 | Passcode: %@!H9LQ=
Session 2 (with French interpretation) | Passcode: %T3QycQ*
